Traws Pharma shares turned volatile after the company completed enrolment in its Phase 2 trial of Ratutrelvir for mild-to-moderate COVID-19. The open-label trial enrolled 90 patients and compared Ratutrelvir with Paxlovid, an oral antiviral medication from Pfizer used to treat mild-to-moderate COVID-19.